New Publications About Bone Marrow Transplant Available for Patients

Publication
Article
OncologyONCOLOGY Vol 12 No 5
Volume 12
Issue 5

Bone marrow transplantation (BMT) is now recognized as standard treatment for many diseases. Patients with cancer, especially those with certain types of leukemia, lymphoma, breast and ovarian cancers, multiple myeloma, and aplastic

Bone marrow transplantation (BMT) is now recognized as standard treatment for many diseases. Patients with cancer, especially those with certain types of leukemia, lymphoma, breast and ovarian cancers, multiple myeloma, and aplastic anemia, increasingly find that a transplant is their best hope for a cure. Interest in this medical procedure has risen tremendously as has the need for information about it.

The National Bone Marrow Transplant Link (nbmtLink) has responded to the increased need for information about BMT. Two publications are now available for patients, family members, and health professionals. They are:

Bone Marrow Transplant Resource Guide—This 25-page booklet provides a complete overview of the transplant process. (Single copies are available to patients at no charge.)

Survivor’s Guide to a Bone Marrow Transplant: What to Expect and How to Get Through It—Written by Keren Stronach, a two-time transplant survivor, this booklet describes the experiences of 25 BMT survivors and offers valuable advice on coping during this period, as well as suggestions on how to prepare for a transplant. (The booklet is available at $9.00 per copy.)

For more information about these publications, contact the nbmtLink office at 800-LINK BMIT (800-546-5268) or call 248-932-8483.

Recent Videos
Combining daratumumab with other agents is one strategy that investigators are exploring in the smoldering multiple myeloma field.
A substantial portion of patients who received daratumumab in the AQUILA study were able to delay disease progression to active multiple myeloma.
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
Although a similar proportion achieved MRD negativity at the 10 to the –6 power, not enough studies have analyzed MRD at this level for multiple myeloma.
Related Content